Diffuse large B-cell lymphomas (DLBCL) are now considered a heterogeneous group of distinct molecular subtypes (germinal center B-cell DLBCL, activated B-cell DLBCL, and primary mediastinal large B-cell lymphoma (PMBL) with varied natural history and response to therapy. In addition, a subset of patients with DLBCL have concurrent MYC and/or BCL2 gene rearrangements (double-hit lymphomas; DHL) and others have a dual expression of both MYC and BCL2 proteins (double-expressing DLBCL; DEL). The standard of care for the treatment of patients with PMBL, DHL, or DEL has not been established. Adequate immunophenotyping and molecular testing (in selected circumstances) are necessary for the accurate diagnosis of different subtypes of DLBCL. The NCCN Guidelines included in this issue, part of the NCCN Guidelines for non-Hodgkin's lymphomas, address the diagnosis and management of DLBCL and its subtypes.

  • 1.

    Al-Hamadani M, Habermann TM, Cerhan JR. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol 2015;90:790795.

    • Search Google Scholar
    • Export Citation
  • 2.

    Alizadeh AA, Eisen MB, Davis RE. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503511.

    • Search Google Scholar
    • Export Citation
  • 3.

    Hans CP, Weisenburger DD, Greiner TC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275282.

    • Search Google Scholar
    • Export Citation
  • 4.

    Choi WWL, Weisenburger DD, Greiner TC. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:54945502.

    • Search Google Scholar
    • Export Citation
  • 5.

    Meyer PN, Fu K, Greiner TC. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011;29:200207.

    • Search Google Scholar
    • Export Citation
  • 6.

    Savage KJ, Johnson NA, Ben-Neriah S. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114:35333537.

    • Search Google Scholar
    • Export Citation
  • 7.

    Barrans S, Crouch S, Smith A. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28:33603365.

    • Search Google Scholar
    • Export Citation
  • 8.

    Tzankov A, Xu-Monette ZY, Gerhard M. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol 2014;27:958971.

    • Search Google Scholar
    • Export Citation
  • 9.

    Nowakowski GS, LaPlant B, Macon WR. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol 2015;33:251257.

    • Search Google Scholar
    • Export Citation
  • 10.

    Wilson WH, Young RM, Schmitz R. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015;21:922926.

    • Search Google Scholar
    • Export Citation
  • 11.

    Mozos A, Royo C, Hartmann E. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009;94:15551562.

    • Search Google Scholar
    • Export Citation
  • 12.

    Zeng W, Fu K, Quintanilla-Fend L. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression. Am J Surg Pathol 2012;36:214219.

    • Search Google Scholar
    • Export Citation
  • 13.

    FDA Drug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab); September 25, 2013. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM369436.pdf.

    • Search Google Scholar
    • Export Citation
  • 14.

    Juweid ME. FDG-PET/CT in lymphoma. Methods Mol Biol 2011;727:119.

  • 15.

    Cheson BD, Fisher RI, Barrington SF. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:30593068.

    • Search Google Scholar
    • Export Citation
  • 16.

    Adams HJ, Kwee TC, de Keizer B. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2014;41:565574.

    • Search Google Scholar
    • Export Citation
  • 17.

    A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987994.

    • Search Google Scholar
    • Export Citation
  • 18.

    Sehn LH, Berry B, Chhanabhai M. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard ipi for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2006;109:18571861.

    • Search Google Scholar
    • Export Citation
  • 19.

    Zhou Z, Sehn LH, Rademaker AW. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123:837842.

    • Search Google Scholar
    • Export Citation
  • 20.

    El-Galaly TC, Villa D, Alzahrani M. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. Am J Hematol 2015;90:10411046.

    • Search Google Scholar
    • Export Citation
  • 21.

    Zucca E, Conconi A, Mughal TI. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003;21:2027.

    • Search Google Scholar
    • Export Citation
  • 22.

    Laskin JJ, Savage KJ, Voss N. Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma 2005;46:17211727.

    • Search Google Scholar
    • Export Citation
  • 23.

    Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 2009;89:577583.

    • Search Google Scholar
    • Export Citation
  • 24.

    Schmitz N, Zeynalova S, Nickelsen M. A new prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. Hematological Oncology 2013;31(Suppl 1):Abstract 047.

    • Search Google Scholar
    • Export Citation
  • 25.

    Savage KJ, Zeynalova S, Kansara RR. Validation of a prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma [abstract]. Blood 2014;124:Abstract 394.

    • Search Google Scholar
    • Export Citation
  • 26.

    Miller TP, Dahlberg S, Cassady JR. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:2126.

    • Search Google Scholar
    • Export Citation
  • 27.

    Shenkier TN, Voss N, Fairey R. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 2002;20:197204.

    • Search Google Scholar
    • Export Citation
  • 28.

    Horning SJ, Weller E, Kim K. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004;22:30323038.

    • Search Google Scholar
    • Export Citation
  • 29.

    Bonnet C, Fillet G, Mounier N. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007;25:787792.

    • Search Google Scholar
    • Export Citation
  • 30.

    Persky DO, Unger JM, Spier CM. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008;26:22582263.

    • Search Google Scholar
    • Export Citation
  • 31.

    Pfreundschuh M, Trumper L, Osterborg A. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379391.

    • Search Google Scholar
    • Export Citation
  • 32.

    Pfreundschuh M, Kuhnt E, Trumper L. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12:10131022.

    • Search Google Scholar
    • Export Citation
  • 33.

    Odejide OO, Cronin AM, Davidoff AJ. Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. Leuk Lymphoma 2015;56:716724.

    • Search Google Scholar
    • Export Citation
  • 34.

    Fisher RI, Gaynor ER, Dahlberg S. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:10021006.

    • Search Google Scholar
    • Export Citation
  • 35.

    Coiffier B, Lepage E, Briere J. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235242.

    • Search Google Scholar
    • Export Citation
  • 36.

    Feugier P, Van Hoof A, Sebban C. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:41174126.

    • Search Google Scholar
    • Export Citation
  • 37.

    Coiffier B, Thieblemont C, Van Den Neste E. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116:20402045.

    • Search Google Scholar
    • Export Citation
  • 38.

    Sonneveld P, van Putten W, Holte H. Intensified CHOP with rituximab for intermediate or high-risk Non-hodgkin's lymphoma: interim analysis of a randomized phase III trial in elderly patients by the Dutch HOVON and Nordic Lymphoma Groups [abstract]. Blood 2005;106:Abstract 16.

    • Search Google Scholar
    • Export Citation
  • 39.

    Habermann TM, Weller EA, Morrison VA. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:31213127.

    • Search Google Scholar
    • Export Citation
  • 40.

    Blayney DW, LeBlanc ML, Grogan T. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 2003;21:24662473.

    • Search Google Scholar
    • Export Citation
  • 41.

    Halaas JL, Moskowitz CH, Horwitz S. R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Leuk Lymphoma 2005;46:541547.

    • Search Google Scholar
    • Export Citation
  • 42.

    Pfreundschuh M, Trumper L, Kloess M. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634641.

    • Search Google Scholar
    • Export Citation
  • 43.

    Pfreundschuh M, Schubert J, Ziepert M. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105116.

    • Search Google Scholar
    • Export Citation
  • 44.

    Pfreundschuh M, Ziepert M, Zeynalova S. Six versus eight cycles of biweekly CHOP-14 with or without R in elderly patients (pts) with aggressive CD20+ B-cell lymphomas: Seven-year FU of the RICOVER-60 trial of the DSHNHL [abstract]. J Clin Oncol 2011;29:Abstract 8029.

    • Search Google Scholar
    • Export Citation
  • 45.

    Held G, Murawski N, Ziepert M. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol 2014;32:11121118.

    • Search Google Scholar
    • Export Citation
  • 46.

    Held G, Zeynalova S, Murawski N. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol 2013;31:41154122.

    • Search Google Scholar
    • Export Citation
  • 47.

    Cunningham D, Hawkes EA, Jack A. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013;381:18171826.

    • Search Google Scholar
    • Export Citation
  • 48.

    Delarue R, Tilly H, Mounier N. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 2013;14:525533.

    • Search Google Scholar
    • Export Citation
  • 49.

    Schmitz N, Nickelsen M, Ziepert M. Optimization of rituximab for treatment of DLBCL in young, high-risk patients-results of the dense-R-CHOEP Trial of the German high-grade lymphoma study group. Blood 2015;126:474474.

    • Search Google Scholar
    • Export Citation
  • 50.

    Pfreundschuh M, Muller C, Zeynalova S. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood 2014;123:640646.

  • 51.

    Pfreundschuh M, Held G, Zeynalova S. Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20+ B-cell lymphomas: results from the SEXIE-R-CHOP-14 trial of the DSHNHL [abstract]. J Clin Oncol 2014;32 (15_suppl):Abstract 8501.

    • Search Google Scholar
    • Export Citation
  • 52.

    Wilson WH, Jung SH, Porcu P. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 2012;97:758765.

    • Search Google Scholar
    • Export Citation
  • 53.

    Purroy N, Bergua J, Gallur L. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. Br J Haematol 2015;169:188198.

    • Search Google Scholar
    • Export Citation
  • 54.

    Peyrade F, Jardin F, Thieblemont C. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460468.

    • Search Google Scholar
    • Export Citation
  • 55.

    Peyrade F, Fain O, Fabiani B. Long-term follow-up of the GELA LNH 03-7B study: a prospective phase II study of 150 patients over 80 years with diffuse large B-cell lymphoma (DLBCL) treated with RminiCHOP [abstract]. J Clin Oncol 2013;31(15_suppl):Abstract 8536.

    • Search Google Scholar
    • Export Citation
  • 56.

    Haioun C, Lepage E, Gisselbrecht C. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol: a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000;18:30253030.

    • Search Google Scholar
    • Export Citation
  • 57.

    Stiff PJ, Unger JM, Cook JR. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 2013;369:16811690.

    • Search Google Scholar
    • Export Citation
  • 58.

    Le Gouill S, Milpied NJ, Lamy T. First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: preliminary results of the GOELAMS 075 prospective multicenter randomized trial [abstract]. J Clin Oncol 2011;29:Abstract 8003.

    • Search Google Scholar
    • Export Citation
  • 59.

    Schmitz N, Nickelsen M, Ziepert M. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 2012;13:12501259.

    • Search Google Scholar
    • Export Citation
  • 60.

    Vitolo U, Chiappella A, Brusamolino E. Rituximab dose-dense chemotherapy followed by intensified high-dose chemotherapy and autologous stem cell transplantation (HDC+ASCT) significantly reduces the risk of progression compared to standard rituximab dose-dense chemotherapy as first line treatment in young patients with high-risk (aa-IPI 2-3) diffuse large B-cell lymphoma (DLBCL): final results of phase III randomized trial DLCL04 of the Fondazione Italiana Linfomi (FIL) [absttract]. Blood 2012;120:Abstract 688.

    • Search Google Scholar
    • Export Citation
  • 61.

    Abramson JS, Hellmann M, Barnes JA. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 2010;116:42834290.

    • Search Google Scholar
    • Export Citation
  • 62.

    Holte H, Leppa S, Bjorkholm M. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol 2013;24:13851392.

    • Search Google Scholar
    • Export Citation
  • 63.

    Cheah CY, Herbert KE, O'Rourke K. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer 2014;111:10721079.

    • Search Google Scholar
    • Export Citation
  • 64.

    Ferreri AJ, Bruno-Ventre M, Donadoni G. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol 2015;168:654662.

    • Search Google Scholar
    • Export Citation
  • 65.

    Kumar A, Vanderplas A, LaCasce AS. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer 2012;118:29442951.

    • Search Google Scholar
    • Export Citation
  • 66.

    Tomita N, Takasaki H, Ishiyama Y. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma 2015;56:725729.

    • Search Google Scholar
    • Export Citation
  • 67.

    Mikhaeel NG, Timothy AR, O'Doherty MJ. 18-FDG-PET as a prognostic1. indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma 2000;39:543553.

    • Search Google Scholar
    • Export Citation
  • 68.

    Spaepen K, Stroobants S, Dupont P. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:13561363.

    • Search Google Scholar
    • Export Citation
  • 69.

    Haioun C, Itti E, Rahmouni A. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:13761381.

    • Search Google Scholar
    • Export Citation
  • 70.

    Dupuis J, Itti E, Rahmouni A. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol 2009;20:503507.

    • Search Google Scholar
    • Export Citation
  • 71.

    Moskowitz CH, Schoder H, Teruya-Feldstein J. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 2010;28:18961903.

    • Search Google Scholar
    • Export Citation
  • 72.

    Pregno P, Chiappella A, Bello M. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood 2012;119:20662073.

    • Search Google Scholar
    • Export Citation
  • 73.

    Carr R, Fanti S, Paez D. Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma. J Nucl Med 2014;55:19361944.

    • Search Google Scholar
    • Export Citation
  • 74.

    Dabaja BS, Vanderplas AM, Crosby-Thompson AL. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer 2015;121:10321039.

    • Search Google Scholar
    • Export Citation
  • 75.

    Mamot C, Klingbiel D, Hitz F. Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). J Clin Oncol 2015;33:25232529.

    • Search Google Scholar
    • Export Citation
  • 76.

    Swinnen LJ, Li H, Quon A. Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). Br J Haematol 2015;170:5665.

    • Search Google Scholar
    • Export Citation
  • 77.

    Barrington SF, Mikhaeel NG, Kostakoglu L. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014;32:30483058.

    • Search Google Scholar
    • Export Citation
  • 78.

    Barrington SF, Qian W, Somer EJ. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010;37:18241833.

    • Search Google Scholar
    • Export Citation
  • 79.

    Meignan M, Gallamini A, Haioun C, Polliack A. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma 2010;51:21712180.

    • Search Google Scholar
    • Export Citation
  • 80.

    Meignan M, Gallamini A, Itti E. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma 2012;53:18761881.

    • Search Google Scholar
    • Export Citation
  • 81.

    Guppy AE, Tebbutt NC, Norman A, Cunningham D. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:123125.

    • Search Google Scholar
    • Export Citation
  • 82.

    Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 2006;17:909913.

    • Search Google Scholar
    • Export Citation
  • 83.

    Zinzani PL, Stefoni V, Tani M. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009;27:17811787.

    • Search Google Scholar
    • Export Citation
  • 84.

    Petrausch U, Samaras P, Haile SR. Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. Ann Oncol 2010;21:16941698.

    • Search Google Scholar
    • Export Citation
  • 85.

    Avivi I, Zilberlicht A, Dann EJ. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Am J Hematol 2013;88:400405.

    • Search Google Scholar
    • Export Citation
  • 86.

    Cheah CY, Hofman MS, Dickinson M. Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer 2013;109:312317.

    • Search Google Scholar
    • Export Citation
  • 87.

    Thompson CA, Ghesquieres H, Maurer MJ. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol 2014;32:35063512.

    • Search Google Scholar
    • Export Citation
  • 88.

    El-Galaly TC, Jakobsen LH, Hutchings M. Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: A Danish-Swedish population-based study. J Clin Oncol 2015;33:39933998.

    • Search Google Scholar
    • Export Citation
  • 89.

    Maurer MJ, Ghesquieres H, Jais JP. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 2014;32:10661073.

    • Search Google Scholar
    • Export Citation
  • 90.

    Philip T, Guglielmi C, Hagenbeek A. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:15401545.

    • Search Google Scholar
    • Export Citation
  • 91.

    Mounier N, Canals C, Gisselbrecht C. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2012;18:788793.

    • Search Google Scholar
    • Export Citation
  • 92.

    Hamlin PA, Zelenetz AD, Kewalramani T. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102:19891996.

    • Search Google Scholar
    • Export Citation
  • 93.

    Lerner RE, Thomas W, Defor TE. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission. Biol Blood Marrow Transplant 2007;13:486492.

    • Search Google Scholar
    • Export Citation
  • 94.

    Derenzini E, Musuraca G, Fanti S. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer 2008;113:24962503.

    • Search Google Scholar
    • Export Citation
  • 95.

    Spaepen K, Stroobants S, Dupont P. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003;102:5359.

    • Search Google Scholar
    • Export Citation
  • 96.

    Trneny M, Bosly A, Bouabdallah K. Independent predictive value of PET-CT pre transplant in relapsed and refractory patients with CD20 diffuse large B-cell lymphoma (DLBCL) included in the CORAL study [abstract]. Blood 2009;114:Abstract 881.

    • Search Google Scholar
    • Export Citation
  • 97.

    Hoppe BS, Moskowitz CH, Zhang Z. The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplant 2009;43:941948.

    • Search Google Scholar
    • Export Citation
  • 98.

    Vose JM, Zhang MJ, Rowlings PA. Autologous transplantation for diffuse aggressive Non-hodgkin's lymphoma in patients never achieving remission: a report from the autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001;19:406413.

    • Search Google Scholar
    • Export Citation
  • 99.

    Caballero MD, Pérez-Simón JA, Iriondo A. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Annals of Oncology 2003;14:140151.

    • Search Google Scholar
    • Export Citation
  • 100.

    Rodriguez J, Caballero MD, Gutierrez A. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Annals of Oncology 2004;15:15041509.

    • Search Google Scholar
    • Export Citation
  • 101.

    Coiffier B, Haioun C, Ketterer N. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:19271932.

    • Search Google Scholar
    • Export Citation
  • 102.

    Mey UJ, Orlopp KS, Flieger D. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest 2006;24:593600.

    • Search Google Scholar
    • Export Citation
  • 103.

    Velasquez WS, McLaughlin P, Tucker S. ESHAP: an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:11691176.

    • Search Google Scholar
    • Export Citation
  • 104.

    Joyce RM, Regan M, Ottaway J. A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT). Ann Oncol 2003;14 Suppl 1:2127.

    • Search Google Scholar
    • Export Citation
  • 105.

    Zelenetz AD, Hamlin P, Kewalramani T. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2003;14 Suppl 1:i510.

    • Search Google Scholar
    • Export Citation
  • 106.

    Vose J, Sneller V. Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma. Ann Oncol 2003;14 Suppl 1:1720.

    • Search Google Scholar
    • Export Citation
  • 107.

    Kewalramani T, Zelenetz AD, Nimer SD. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:36843688.

    • Search Google Scholar
    • Export Citation
  • 108.

    Gutierrez M, Chabner BA, Pearson D. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000;18:36333642.

    • Search Google Scholar
    • Export Citation
  • 109.

    Jermann M, Jost LM, Taverna C. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 2004;15:511516.

    • Search Google Scholar
    • Export Citation
  • 110.

    Chao NJ, Rosenberg SA, Horning SJ. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood 1990;76:12931298.

    • Search Google Scholar
    • Export Citation
  • 111.

    Gisselbrecht C, Glass B, Mounier N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era J Clin Oncol 2010;28:41844190.

    • Search Google Scholar
    • Export Citation
  • 112.

    Gisselbrecht C, Schmitz N, Mounier N. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. J Clin Oncol 2012;30:44624469.

    • Search Google Scholar
    • Export Citation
  • 113.

    Cuccuini W, Briere J, Mounier N. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 2012;119:46194624.

    • Search Google Scholar
    • Export Citation
  • 114.

    Thieblemont C, Briere J, Mounier N. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011;29:40794087.

    • Search Google Scholar
    • Export Citation
  • 115.

    Crump M, Baetz T, Couban S. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004;101:18351842.

    • Search Google Scholar
    • Export Citation
  • 116.

    El Gnaoui T, Dupuis J, Belhadj K. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007;18:13631368.

    • Search Google Scholar
    • Export Citation
  • 117.

    Lopez A, Gutierrez A, Palacios A. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol 2008;80:127132.

    • Search Google Scholar
    • Export Citation
  • 118.

    Corazzelli G, Capobianco G, Arcamone M. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol 2009;64:907916.

    • Search Google Scholar
    • Export Citation
  • 119.

    Mounier N, El Gnaoui T, Tilly H. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica 2013;98:17261731.

    • Search Google Scholar
    • Export Citation
  • 120.

    Crump M, Kuruvilla J, Couban S. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014;32:34903496.

    • Search Google Scholar
    • Export Citation
  • 121.

    Weidmann E, Kim SZ, Rost A. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:12851289.

    • Search Google Scholar
    • Export Citation
  • 122.

    Ogura M, Ando K, Taniwaki M. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma(6). Cancer Sci 2011;102:16871692.

    • Search Google Scholar
    • Export Citation
  • 123.

    Ohmachi K, Niitsu N, Uchida T. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2013;31:21032109.

    • Search Google Scholar
    • Export Citation
  • 124.

    Vacirca JL, Acs PI, Tabbara IA. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol 2014;93:403409.

    • Search Google Scholar
    • Export Citation
  • 125.

    Wiernik PH, Lossos IS, Tuscano JM. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26:49524957.

    • Search Google Scholar
    • Export Citation
  • 126.

    Witzig TE, Vose JM, Zinzani PL. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011;22:16221627.

    • Search Google Scholar
    • Export Citation
  • 127.

    Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011;117:50585066.

    • Search Google Scholar
    • Export Citation
  • 128.

    Wang M, Fowler N, Wagner-Bartak N. Oral Lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. Leukemia 2013;27:19021909.

    • Search Google Scholar
    • Export Citation
  • 129.

    Zinzani PL, Vose JM, Czuczman MS. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol 2013;24:28922897.

    • Search Google Scholar
    • Export Citation
  • 130.

    Czuczman MS, Davies A, Linton KM. A Phase 2/3 multicenter, randomized study comparing the efficacy and safety of lenalidomide versus investigator's choice in relapsed/refractory DLBCL. Blood 2014;124:628628.

    • Search Google Scholar
    • Export Citation
  • 131.

    Jacobsen ED, Sharman JP, Oki Y. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 2015;125:13941402.

    • Search Google Scholar
    • Export Citation
  • 132.

    Hoppe BS, Moskowitz CH, Filippa DA. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity. J Clin Oncol 2008;26:18581864.

    • Search Google Scholar
    • Export Citation
  • 133.

    Cazals-Hatem D, Lepage E, Brice P. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d'Etude des Lymphomes de l'Adulte”) study. Am J Surg Pathol 1996;20:877888.

    • Search Google Scholar
    • Export Citation
  • 134.

    Faris JE, LaCasce AS. Primary mediastinal large B-cell lymphoma. Clin Adv Hematol Oncol 2009;7:125133.

  • 135.

    Rosenwald A, Wright G, Leroy K. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851862.

    • Search Google Scholar
    • Export Citation
  • 136.

    Savage KJ, Monti S, Kutok JL. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003;102:38713879.

    • Search Google Scholar
    • Export Citation
  • 137.

    Hamlin PA, Portlock CS, Straus DJ. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol 2005;130:691699.

    • Search Google Scholar
    • Export Citation
  • 138.

    Savage KJ, Al-Rajhi N, Voss N. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006;17:123130.

    • Search Google Scholar
    • Export Citation
  • 139.

    Todeschini G, Secchi S, Morra E. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004;90:372376.

    • Search Google Scholar
    • Export Citation
  • 140.

    Zinzani PL, Martelli M, Bertini M. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002;87:12581264.

    • Search Google Scholar
    • Export Citation
  • 141.

    De Sanctis V, Finolezzi E, Osti MF. MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma. Int J Radiat Oncol Biol Phys 2008;72:11541160.

    • Search Google Scholar
    • Export Citation
  • 142.

    Mazzarotto R, Boso C, Vianello F. Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients: a single institution experience. Int J Radiat Oncol Biol Phys 2007;68:823829.

    • Search Google Scholar
    • Export Citation
  • 143.

    Zinzani PL, Stefoni V, Finolezzi E. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma 2009;9:381385.

    • Search Google Scholar
    • Export Citation
  • 144.

    Rieger M, Osterborg A, Pettengell R. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011;22:664670.

    • Search Google Scholar
    • Export Citation
  • 145.

    Vassilakopoulos TP, Pangalis GA, Katsigiannis A. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist 2012;17:239249.

    • Search Google Scholar
    • Export Citation
  • 146.

    Witzens-Harig M, Ho AD, Kuhnt E. Primary mediastinal B cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: 5-year results of the Mabthera International Trial Group (MInT) study [abstract]. Blood 2012;120:Abstract 1612.

    • Search Google Scholar
    • Export Citation
  • 147.

    Avigdor A, Sirotkin T, Kedmi M. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. Ann Hematol 2014;93:12971304.

    • Search Google Scholar
    • Export Citation
  • 148.

    Moskowitz C, Hamlin PA Jr., Maragulia J. Sequential dose-dense RCHOP followed by ICE consolidation (MSKCC protocol 01-142) without radiotherapy for patients with primary mediastinal large B-cell lymphoma[abstract]. Blood 2010;116:Abstract 420.

    • Search Google Scholar
    • Export Citation
  • 149.

    Soumerai JD, Hellmann MD, Feng Y. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma 2014;55:538543.

    • Search Google Scholar
    • Export Citation
  • 150.

    Dunleavy K, Pittaluga S, Maeda LS. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013;368:14081416.

    • Search Google Scholar
    • Export Citation
  • 151.

    Binkley MS, Hiniker SM, Wu S. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Leuk Lymphoma 2015:15.

    • Search Google Scholar
    • Export Citation
  • 152.

    Martelli M, Ceriani L, Zucca E. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol 2014;32:17691775.

    • Search Google Scholar
    • Export Citation
  • 153.

    Pinnix CC, Dabaja B, Ahmed MA. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 2015;92:113121.

    • Search Google Scholar
    • Export Citation
  • 154.

    Jaffe ES, Stein H, Swerdlow SH. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL., eds. WHO classification of tumours of haematopoietic and lymphoid tissues (ed 4th). Lyon: IARC; 2008:267268.

    • Search Google Scholar
    • Export Citation
  • 155.

    Quintanilla-Martinez L, de Jong D, de Mascarel A. Gray zones around diffuse large B cell lymphoma: conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France. J Hematop 2009;2:211236.

    • Search Google Scholar
    • Export Citation
  • 156.

    Hoeller S, Copie-Bergman C. Grey zone lymphomas: lymphomas with intermediate features. Adv Hematol 2012;2012:460801.

  • 157.

    Gualco G, Natkunam Y, Bacchi CE. The spectrum of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a description of 10 cases. Mod Pathol 2012;25:661674.

    • Search Google Scholar
    • Export Citation
  • 158.

    Evens AM, Kanakry JA, Sehn LH. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol 2015;90:778783.

    • Search Google Scholar
    • Export Citation
  • 159.

    Traverse-Glehen A, Pittaluga S, Gaulard P. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 2005;29:14111421.

    • Search Google Scholar
    • Export Citation
  • 160.

    Eberle FC, Rodriguez-Canales J, Wei L. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica 2011;96:558566.

    • Search Google Scholar
    • Export Citation
  • 161.

    Garcia JF, Mollejo M, Fraga M. Large B-cell lymphoma with Hodgkin's features. Histopathology 2005;47:101110.

  • 162.

    Wilson WH, Pittaluga S, Nicolae A. A prospective study of mediastinal gray-zone lymphoma. Blood 2014;124:15631569.

  • 163.

    Green TM, Young KH, Visco C. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:34603467.

    • Search Google Scholar
    • Export Citation
  • 164.

    Johnson NA, Slack GW, Savage KJ. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:34523459.

    • Search Google Scholar
    • Export Citation
  • 165.

    Snuderl M, Kolman OK, Chen YB. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010;34:327340.

    • Search Google Scholar
    • Export Citation
  • 166.

    Le Gouill S, Talmant P, Touzeau C. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 2007;92:13351342.

    • Search Google Scholar
    • Export Citation
  • 167.

    Aukema SM, Siebert R, Schuuring E. Double-hit B-cell lymphomas. Blood 2011;117:23192331.

  • 168.

    Petrich AM, Gandhi M, Jovanovic B. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood 2014;124:23542361.

    • Search Google Scholar
    • Export Citation
  • 169.

    Oki Y, Noorani M, Lin P. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 2014;166:891901.

  • 170.

    Sun H, Savage KJ, Karsan A. Outcome of patients with non-Hodgkin lymphomas with concurrent MYC and BCL2 rearrangements treated with CODOX-M/IVAC with rituximab followed by hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk 2015;15:341348.

    • Search Google Scholar
    • Export Citation
  • 171.

    Howlett C, Snedecor SJ, Landsburg DJ. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol 2015;170:504514.

    • Search Google Scholar
    • Export Citation
  • 172.

    Dunleavy K, Fanale M, LaCasce A. Preliminary report of a multicenter prospective phase ii study of DA-EPOCH-R in MYC-rearranged aggressive b-cell lymphoma [abstract]. Blood 2014;124:Abstract

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 762 491 37
PDF Downloads 285 196 8
EPUB Downloads 0 0 0